Journal of Medicinal Chemistry
January 12, 2023
Carolyn J Straub, Lisa E Rusali, Kyle M Kremiller et al.
19 citations
For decades, ibogaine─the main psychoactive alkaloid found in Tabernanthe iboga─has been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of α3β4 nicotinic acetylcholine receptors (nAChRs),...
Current Neuropharmacology
October 20, 2022
Alessio Mosca, Stefania Chiappini, Andrea Miuli et al.
30 citations
BACKGROUND: Ibogaine and noribogaine are psychedelic substances with dissociative properties naturally occurring in plants of the Apocynaceae family. Research has shown their efficacy in treating substance use disorders (SUD), particularly in opiate detoxification, but their efficacy and toxicity are still unclear. OBJECTIVE: This review aims to assess the anti-addictive role of ibogaine and...
Health Psychology Research
October 6, 2022
Amber N. Edinoff, Natalie W. Wu, Bryce Bonin et al.
11 citations
Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist...
Anthropology of Consciousness
July 8, 2022
Bruno Ramos Gomes, Luís Fernando Tófoli
2 citations
ABSTRACT This research qualitatively investigated four treatments for addiction in Brazil that use ibogaine as the main tool in the process. Ibogaine is a substance derived from an African plant, Tabernanthe iboga, traditionally used in its region of origin and which leads to intense sensations during its acute effects and also different experiences of oneself and the surrounding world in the...
Journal of Substance Abuse Treatment
July 1, 2022
Patrick Köck, Katharina Froelich, Marc Walter et al.
68 citations
Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and...
Addiction (Abingdon, England)
2022
Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al.
49 citations
Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine...
May 28, 2021
Bruno Ramos Gomes
This research qualitatively investigated four treatments for addiction currently in Brazi that use ibogaine as the main tool in the process.Ibogaine is a substance derived from an African plant, Tabernanthe iboga, traditionally used in its region of origin and which leads to intense changes in physical and psychic sensations, considered a psychedelic.Before entering the field, an integrative...
Synfacts
February 16, 2021
Dirk Trauner, Andrej Shemet
Key words psychedelics - drug development - function-oriented synthesis - Fischer indole synthesis Publication History Publication Date: 16 February 2021 (online) © 2021. Thieme. All rights reserved Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Neuroscience insights
2021
Jamie Peters, David E. Olson
38 citations
Addiction is best described as a disorder of maladaptive neuroplasticity involving the simultaneous strengthening of reward circuitry that drives compulsive drug seeking and weakening of circuits involved in executive control over harmful behaviors. Psychedelics have shown great promise for treating addiction, with many people attributing their therapeutic effects to insights gained while under...
The International journal on drug policy
September 1, 2020
Michaela Barber, John Gardner, Michael Savic et al.
16 citations
Background Ibogaine is a psychedelic drug used by for-profit clinics and lay-people to treat addiction, despite some reported fatalities and a lack of rigorous clinical research. Little is known about ibogaine therapy from a consumer perspective. Online discussions generate and disseminate information about ibogaine therapy and provide a window into how people understand ibogaine's risks and...